TPO-Mimetic Use in Children for Hemotopoietic Failure
-
- STATUS
- Recruiting
-
- End date
- Dec 3, 2022
-
- participants needed
- 25
-
- sponsor
- Anjali Sharathkumar
Summary
This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.
Description
This investigator-initiated study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders (BMF) including acquired and inherited conditions as a first line of therapy along with standard of care.
Objectives: Primary objectives are to evaluate safety and preliminary efficacy of Romiplostim in children with BMF. Methods: This open label, prospective Pilot interventional study has two arms.
Arm A will include acquired bone marrow failure (BMF) disorders including aplastic anemia, refractory cytopenia of childhood without monosomy 7 and 5q deletion abnormalities, toxin induced myelosuppression due to infection and inherited cytopenia with or without involvement of other cell lines who are transfusion dependent and or showing progression to bone marrow failure. Arm B will include children with chemo and or radiotherapy induced thrombocytopenia/cytopenia and children undergoing stem cell transplantation (SCT). Children with cancer predisposition and other morbidities which are considered significant by the investigator will be excluded from the study.
Details
| Condition | Refractory Cytopenia of Childhood, Anemia; Non-Hodgkin’s Lymphoma, Thrombocytopenia, myelodysplastic syndromes, Bone Marrow Failure Disorders, Thrombocytopenia and Thrombocytopenia Prevention, Aplastic Anemia, myelodysplastic syndrome (mds), Anemia; Non-Small-Cell Lung Cancer, Bone marrow disorder, Red Blood Cell Disorders, Myelodysplastic Syndromes (MDS), Anemia, MYELODYSPLASTIC SYNDROME, Bone Marrow Failure Syndromes, Preleukemia, Bone Marrow Disorder |
|---|---|
| Treatment | romiplostim |
| Clinical Study Identifier | NCT04478227 |
| Sponsor | Anjali Sharathkumar |
| Last Modified on | 18 June 2021 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer